{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:31:58Z","timestamp":1790688718559,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Idiopathic intracranial hypertension (IIH) is becoming increasingly more prevalent bearing the risk of visual impairment and affecting the quality of life. Clinical presentation and outcome are heterogeneous. Large, well-characterized cohorts are scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To characterize the clinical spectrum, diagnostic findings, therapeutic management, and outcome of IIH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified patients with IIH according to modified Friedman criteria treated at our center between 2014 and 2021. The Vienna IIH database is described in detail.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 113 patients 89% were female (mean age 32.3\u00a0years). Median body mass index (BMI) was 31.8, with 85% overweight (BMI\u202f&gt;\u200925) and 5% were classified as IIH without papilledema. Headache was present in 84% and showed migraine features in 43%. Median opening pressure in lumbar puncture was 31\u202fcmH<jats:sub>2<\/jats:sub>O. Pharmacotherapy (predominantly acetazolamide) was established in 99%, 56% required at least 1 therapeutic lumbar puncture and 13% a surgical intervention. After a median 3.7\u00a0years follow-up, 57% had achieved significant weight loss, papilledema was present in 59% and headache in 76% (58% improved). Comparing initial presentation to follow-up, perimetry was abnormal in 67% vs. 50% (8% worsened, 24% improved) and transorbital sonography in 87% vs. 65% with a\u00a0median optic nerve sheath diameter of 5.4\u202fmm vs. 4.9\u202fmm. Median peripapillary retinal nerve fiber layer thickness decreased from 199\u202f\u00b5m to 99\u202f\u00b5m and ganglion cell layer volume from 1.13\u202fmm<jats:sup>3<\/jats:sup> to 1.05\u202fmm<jats:sup>3<\/jats:sup>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The large representative Vienna IIH cohort characterizes IIH-related symptoms, diagnostic findings, treatment, and outcome emphasizing substantial long-term sequelae of IIH. Future analyses will aim to refine phenotyping and identify factors predicting outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00508-023-02252-x","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T02:01:57Z","timestamp":1693447317000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Vienna idiopathic intracranial hypertension database\u2014An Austrian registry"],"prefix":"10.1007","volume":"136","author":[{"given":"Philip","family":"Pruckner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Macher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik","family":"Krajnc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Marik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"W\u00f6ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Pemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-0851","authenticated-orcid":false,"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"50","key":"2252_CR1","first-page":"78","volume":"1993","author":"K Radhakrishnan","year":"1976","unstructured":"Radhakrishnan\u00a0K, Ahlskog\u00a0JE, Cross\u00a0SA, et\u00a0al. Idiopathic intracranial hypertension (Pseudotumor Cerebri): Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1976to;1993(50):78\u201380.","journal-title":"Arch Neurol"},{"key":"2252_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011463","author":"L Miah","year":"2021","unstructured":"Miah\u00a0L, Strafford\u00a0H, Fonferko-Shadrach\u00a0B, et al. Incidence, prevalence and healthcare outcomes in idiopathic intracranial hypertension: A population study. Neurology. 2021; https:\/\/doi.org\/10.1212\/WNL.0000000000011463.","journal-title":"Neurology"},{"key":"2252_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/ene.13739","volume":"25","author":"G McCluskey","year":"2018","unstructured":"McCluskey\u00a0G, Doherty-Allan\u00a0R, McCarron\u00a0P, et al. Meta-analysis and systematic review of population-based epidemiological studies in idiopathic intracranial hypertension. Eur J Neurol. 2018;25:1218\u201327.","journal-title":"Eur J Neurol"},{"key":"2252_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jns.2004.05.009","volume":"223","author":"JA Galvin","year":"2004","unstructured":"Galvin\u00a0JA, Stavern\u00a0GPV. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J\u00a0Neurol Sci. 2004;223:157\u201360.","journal-title":"J Neurol Sci"},{"key":"2252_CR5","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","volume":"81","author":"DI Friedman","year":"2013","unstructured":"Friedman\u00a0DI, Liu\u00a0GT, Digre\u00a0KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81:1159\u201365.","journal-title":"Neurology"},{"key":"2252_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1874364101307010026","volume":"7","author":"J Best","year":"2013","unstructured":"Best\u00a0J, Silvestri\u00a0G, Burton\u00a0B, et\u00a0al. The incidence of blindness due to idiopathic intracranial hypertension in the UK. Open Ophthalmol\u00a0J. 2013;7:26\u20139.","journal-title":"Open Ophthalmol J"},{"key":"2252_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/archneur.1982.00510200003001","volume":"39","author":"JJ Corbett","year":"1982","unstructured":"Corbett\u00a0JJ, Savino\u00a0PJ, Thompson\u00a0HS, et al. Visual loss in pseudotumor cerebri: Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. 1982;39:461\u201374.","journal-title":"Arch Neurol"},{"key":"2252_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/head.13153","volume":"57","author":"DI Friedman","year":"2017","unstructured":"Friedman\u00a0DI, Quiros\u00a0PA, Subramanian\u00a0PS, et\u00a0al. Headache in idiopathic intracranial hypertension: Findings from the idiopathic intracranial hypertension treatment trial. Headache. 2017;57:1195\u2013205.","journal-title":"Headache"},{"key":"2252_CR9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2014.3312","volume":"311","author":"M Wall","year":"2014","unstructured":"Wall\u00a0M, McDermott\u00a0MP, Kieburtz\u00a0KD, et\u00a0al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: The Idiopathic Intracranial Hypertension Treatment Trial. JAMA. 2014;311:1641\u201351.","journal-title":"JAMA"},{"key":"2252_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00701-016-3010-2","volume":"159","author":"AV Kalyvas","year":"2017","unstructured":"Kalyvas\u00a0AV, Hughes\u00a0M, Koutsarnakis\u00a0C, et\u00a0al. Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a\u00a0systematic review of the literature. Acta Neurochir. 2017;159:33\u201349.","journal-title":"Acta Neurochir"},{"key":"2252_CR11","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1111\/j.1467-789X.2010.00799.x","volume":"12","author":"D Friesner","year":"2011","unstructured":"Friesner\u00a0D, Rosenman\u00a0R, Lobb\u00a0BM, et\u00a0al. Idiopathic intracranial hypertension in the USA: the role of obesity in establishing prevalence and healthcare costs. Obes Rev. 2011;12:e372\u2013e80.","journal-title":"Obes Rev"},{"key":"2252_CR12","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/j.1468-1331.2011.03372.x","volume":"18","author":"N Raoof","year":"2011","unstructured":"Raoof\u00a0N, Sharrack\u00a0B, Pepper\u00a0IM, et\u00a0al. The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK. Eur J Neurol. 2011;18:1266\u20138.","journal-title":"Eur J Neurol"},{"key":"2252_CR13","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1167\/iovs.02-1100","volume":"44","author":"DA Rosser","year":"2003","unstructured":"Rosser\u00a0DA, Cousens\u00a0SN, Murdoch\u00a0IE, et\u00a0al. How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Invest Ophthalmol Vis Sci. 2003;44:3278\u201381.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2252_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.45.1.13","volume":"45","author":"L Fris\u00e9n","year":"1982","unstructured":"Fris\u00e9n\u00a0L. Swelling of the optic nerve head: a\u00a0staging scheme. J\u00a0Neurol Neurosurg Psychiatry. 1982;45:13.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2252_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1352458514538110","volume":"21","author":"S Schippling","year":"2014","unstructured":"Schippling\u00a0S, Balk\u00a0L, Costello\u00a0F, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler. 2014;21:163\u201370.","journal-title":"Mult Scler"},{"key":"2252_CR16","first-page":"203","volume":"14","author":"KC Ossoinig","year":"1975","unstructured":"Ossoinig\u00a0KC. A\u2011scan echography and orbital disease. Mod Problems Ophthalmol. 1975;14:203\u201335.","journal-title":"Mod Problems Ophthalmol"},{"key":"2252_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IIO.0b013e3182aabf11","volume":"54","author":"J Chen","year":"2014","unstructured":"Chen\u00a0J, Wall\u00a0M. Epidemiology and risk factors for idiopathic intracranial hypertension. Int Ophthalmol Clin. 2014;54:1\u201311.","journal-title":"Int Ophthalmol Clin"},{"key":"2252_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.58.10.1551","volume":"58","author":"DI Friedman","year":"2002","unstructured":"Friedman\u00a0DI, Rausch\u00a0EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology. 2002;58:1551\u20133.","journal-title":"Neurology"},{"key":"2252_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1526-4610.2008.01324.x","volume":"49","author":"KB Digre","year":"2009","unstructured":"Digre\u00a0KB, Nakamoto\u00a0BK, Warner\u00a0JEA, et\u00a0al. A\u00a0comparison of idiopathic intracranial hypertension with and without papilledema. Headache. 2009;49:185\u201393.","journal-title":"Headache"},{"key":"2252_CR20","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0161-6420(98)99039-X","volume":"105","author":"MC Brodsky","year":"1998","unstructured":"Brodsky\u00a0MC, Vaphiades\u00a0M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology. 1998;105:1686\u201393.","journal-title":"Ophthalmology"},{"key":"2252_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00041327-200103000-00003","volume":"21","author":"A Kesler","year":"2001","unstructured":"Kesler\u00a0A, Gadoth\u00a0N. Epidemiology of idiopathic intracranial hypertension in Israel. J\u00a0Neuroophthalmol. 2001;21:12\u20134.","journal-title":"J Neuroophthalmol"},{"key":"2252_CR22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/head.13144","volume":"57","author":"SV Smith","year":"2017","unstructured":"Smith\u00a0SV, Friedman\u00a0DI. The Idiopathic Intracranial Hypertension Treatment Trial: A review of the outcomes. Headache. 2017;57:1303\u201310.","journal-title":"Headache"},{"issue":"Pt 1A","key":"2252_CR23","first-page":"155","volume":"114","author":"M Wall","year":"1991","unstructured":"Wall\u00a0M, George\u00a0D. Idiopathic intracranial hypertension. A\u00a0prospective study of 50\u00a0patients. Brain J Neurol. 1991;114(Pt 1A):155\u201380.","journal-title":"Brain J Neurol"},{"key":"2252_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1034\/j.1600-0404.2002.02027.x","volume":"106","author":"N \u00c7elebisoy","year":"2002","unstructured":"\u00c7elebisoy\u00a0N, Se\u00e7il\u00a0Y, Aky\u00fcrekli \u00d6. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand. 2002;106:367\u201370.","journal-title":"Acta Neurol Scand"},{"key":"2252_CR25","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1167\/iovs.16-21089","volume":"58","author":"J-K Wang","year":"2017","unstructured":"Wang\u00a0J\u2011K, Kardon\u00a0RH, Ledolter\u00a0J, et al. Peripapillary retinal pigment epithelium layer shape changes from acetazolamide treatment in the idiopathic intracranial hypertension treatment trial. pRPE\/BM shape measure change in IIH. Invest Ophth Vis Sci. 2017;58:2554\u201365.","journal-title":"Invest Ophth Vis Sci"},{"key":"2252_CR26","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00415-017-8532-x","volume":"264","author":"P Albrecht","year":"2017","unstructured":"Albrecht\u00a0P, Blasberg\u00a0C, Ringelstein\u00a0M, et\u00a0al. Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. J\u00a0Neurol. 2017;264:1370\u201380.","journal-title":"J Neurol"},{"key":"2252_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/OPX.0000000000001148","volume":"94","author":"R Saenz","year":"2017","unstructured":"Saenz\u00a0R, Cheng\u00a0H, Prager\u00a0TC, et al. Use of a\u2011scan ultrasound and optical coherence tomography to differentiate papilledema from pseudopapilledema. Optometry Vision Sci. 2017;94:1081\u20139.","journal-title":"Optometry Vision Sci"},{"key":"2252_CR28","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.ophtha.2015.06.003","volume":"122","author":"P Auinger","year":"2015","unstructured":"Auinger\u00a0P, Durbin\u00a0M, Feldon\u00a0S, et\u00a0al. Papilledema outcomes from the optical coherence tomography substudy of the Idiopathic Intracranial Hypertension Treatment Trial. Ophthalmology. 2015;122:1939\u20131945.e2.","journal-title":"Ophthalmology"},{"key":"2252_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaneurol.2021.0659","volume":"78","author":"SP Mollan","year":"2021","unstructured":"Mollan\u00a0SP, Mitchell\u00a0JL, Ottridge\u00a0RS, et\u00a0al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension. JAMA Neurol. 2021;78:678\u201386.","journal-title":"JAMA Neurol"},{"key":"2252_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00415-017-8699-1","volume":"265","author":"P Lochner","year":"2018","unstructured":"Lochner\u00a0P, Fassbender\u00a0K, Lesmeister\u00a0M, et\u00a0al. Ocular ultrasound for monitoring pseudotumor cerebri syndrome. J\u00a0Neurol. 2018;265:356\u201361.","journal-title":"J Neurol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02252-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T10:50:29Z","timestamp":1704797429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":30,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02252-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"24 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Pruckner, C.\u00a0Mitsch, S.\u00a0Macher, W.\u00a0Marik, K.\u00a0Novak and B.\u00a0Pemp declare that they have no competing interests. N.\u00a0Krajnc: has participated in meetings sponsored by and received speaker honoraria or travel funding from Merck, Novartis and Roche, and held a\u00a0grant for a\u00a0Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). C.\u00a0W\u00f6ber: has received honoraria consultancy\/speaking from Apomedica, Curelator, Eli Lilly, Gr\u00fcnenthal, Hermes, Novartis, Pfizer, and Ratiopharm\/Teva. G.\u00a0Bsteh: has participated in meetings sponsored by and received speaker honoraria or travel funding from Biogen, Celgene\/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting from Biogen, Celgene\/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene\/BMS and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}